Griffin Asset Management Inc. Grows Holdings in Pfizer Inc. $PFE

Griffin Asset Management Inc. raised its position in Pfizer Inc. (NYSE:PFE) by 18.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 128,800 shares of the biopharmaceutical company’s stock after buying an additional 20,134 shares during the period. Griffin Asset Management Inc.’s holdings in Pfizer were worth $3,122,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares in the last quarter. Northern Trust Corp increased its stake in shares of Pfizer by 6.8% during the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares in the last quarter. Amundi increased its stake in shares of Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares in the last quarter. Invesco Ltd. increased its stake in shares of Pfizer by 2.8% during the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock worth $767,709,000 after purchasing an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Pfizer by 7.0% during the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock worth $715,581,000 after purchasing an additional 1,846,436 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $24.81 on Monday. The company’s 50-day moving average is $24.86 and its two-hundred day moving average is $24.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.82. The firm has a market capitalization of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the business posted $0.60 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is currently 91.49%.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Bank of America boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.